This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Market Preview: A Reason to Rally

Shares of the drug store operator are up roughly 10% in the past year, and Credit Suisse wasn't feeling too confident ahead of the print. The firm, which has a neutral rating and $38 price target on the stock, says earnings risk "looks high" for quarter and it's expecting a below-consensus profit of 51 to 53 cents a share.

"We believe Walgreens remains one of the most controversial and mistrusted names within consumer," Credit Suisse said. "Q4 sets up to be another marquee event, given recent operational headwinds, the many moving parts to this story, and the possibility for more detailed guidance. We see risk to the Q4 consensus estimate, both from technical and operational issues, but the 2013 outlook seems to be setting up more favorably. While there is risk in the near-term and numerous long-term structural challenges, we openly admit the stock seems to set up positively over the next few quarters given negative investor sentiment and improving momentum."

Despite an anticipated "strong" contribution from demand for generics, Credit Suisse expects fourth-quarter sales to be challenging and said it thinks Walgreen is also shouldering some costs from launching its loyalty program and preparing for the return of Express Scripts (ESRX) customers.

About fiscal 2013 though, the firm was feeling more optimistic.

"We project 2013 EPS at $3.05 (from $3.00), roughly in line with consensus of $3.06," Credit Suisse said. "Earnings momentum should shift positively at Walgreens in 2013, as some ESRX customers return, the company cycles easy flu and front-end comparisons, the generic wave accelerates, and synergies/accretion from AB kick-in. While there are headwinds, such as a MHS pricing reset, loyalty card/ESRX related costs, and an overall challenging competitive/consumer environment, we still see solid growth in earnings."

A slight majority of the sell side is still in wait-and-see mode on Walgreen with 16 of the 26 analysts covering the stock at hold (13), underperform (2) and sell (1). The median 12-month price target on the shares is $39 vs. Thursday's closing price of $36.60.

Check out TheStreet's quote page for Walgreen for year-to-date share performance, analyst ratings, earnings estimates and much more.

The economic calendar includes personal income and spending data for August at 8:30 a.m. ET; the Chicago purchasing managers index for September at 9:45 a.m. ET; and the final reading of the University of Michigan consumer sentiment index at 9:55 a.m. ET.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
FB $79.50 -0.32%
WAG $81.65 2.05%
AAPL $129.19 0.08%
GOOG $574.18 0.50%
TSLA $199.94 1.30%

Markets

DOW 18,188.12 -100.51 -0.55%
S&P 500 2,107.46 -9.93 -0.47%
NASDAQ 4,979.5680 -28.5280 -0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs